Atea Pharmaceuticals Inc (AVIR)vsBeiGene, Ltd. (ONC)
AVIR
Atea Pharmaceuticals Inc
$5.33
-4.31%
HEALTHCARE · Cap: $450.94M
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 2680% more annual revenue ($5.34B vs $192.18M). ONC leads profitability with a 5.4% profit margin vs 0.0%. AVIR earns a higher WallStSmart Score of 54/100 (C-).
AVIR
Buy54
out of 100
Grade: C-
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AVIR.
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
3.0% revenue growth
2.6% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AVIR
The strongest argument for AVIR centers on Debt/Equity, Altman Z-Score, Price/Book.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : AVIR
The primary concerns for AVIR are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
AVIR profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.
ONC carries more volatility with a beta of 0.52 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
AVIR scores higher overall (54/100 vs 42/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Atea Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapies for patients suffering from viral infections. The company is headquartered in Boston, Massachusetts.
Visit Website →BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?